Cytidine 5′-triphosphate (disodium salt) Clinical Trials

Size	Price	Qty
25mg	USD 147

Clinical Trials

Multiple clinical trials are evaluating interventions for conditions such as spontaneous bacterial peritonitis, liver cirrhosis, and acute ischemic stroke. Sponsored by institutions including the Institute of Liver and Biliary Sciences in India and the University of Edinburgh in partnership with NHS Lothian, these unassigned or phase-not-applicable studies vary in operational status, with some currently not yet recruiting while others are actively recruiting participants.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06199843	Not yet recruiting	Spontaneous Bacterial Peritonitis	Institute of Liver and Biliary Sciences India	2024-01-05	Not Applicable
NCT06041932	Not yet recruiting	Liver Cirrhosis	Institute of Liver and Biliary Sciences India	2023-11-01	Not Applicable
NCT06028802	Recruiting	Ischemic Stroke Acute	University of Edinburgh\|NHS Lothian	2023-10-26	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Cytidine 5′-triphosphate (disodium salt) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Cytidine 5′-triphosphate functions as a pyrimidine nucleoside triphosphate substrate that binds to RNA polymerases and cytidylyltransferases to drive RNA synthesis and membrane phospholipid assembly. By sustaining essential transcriptional processes and cellular lipid biosynthesis, it preserves cell survival and structural integrity, which connects to clinical research in liver cirrhosis, spontaneous bacterial peritonitis, and acute ischemic stroke.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).